Anteris Technologies Global Corp.AVR

NasdaqHealthcareOrthopedic, Prosthetic & Surgical Appliances & Supplies
Price (close)
$7.69
Market cap
$749.1M
P/E
—
Revenue (TTM)
$2.2M
Net income
-$103.6M
Dividend yield
—
1-year total return
80.9%
Net margin
-4619.3%
Revenue growth
-9.6%
Debt / equity
0.00x

What Anteris Technologies Global Corp. does.

Anteris is a structural heart company dedicated to revolutionizing cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. Our lead product, the DurAVR ® THV System, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis — a potentially life-threatening condition resulting from a narrowing of the aortic valve. The balloon-expandable DurAVR ® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Our DurAVR ® THV System consists of a single-piece, biomimetic valve made with our proprietary ADAPT ® tissue-enhancing technology and deployed with our balloon expandable ComASUR ® Delivery System. ADAPT ® is our proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Our patented ADAPT ® tissue has been clinically demonstrated to be calcium free for up to 10 years post-procedure, according to Performance of the ADAPT-Treated CardioCel ® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes , published by William Neethling et. al., and has been distributed for use in over 55,000 patients globally in other indications. Our balloon expandable ComASUR ® Delivery System, which was developed in consultation with physicians, is designed to provide precise alignment with the heart’s native commissures to achieve accurate placement of the DurAVR ® THV. As of December 2025, more than 130 patients have been implanted with the DurAVR ® THV worldwide.

Revenue and profit, by fiscal year.

Fiscal year202320242025
Revenue—$2.7M$1.9M
Net income—-$76.3M-$94.1M
Free cash flow—-$63.5M-$79.8M

More on AVR.

Figures from Anteris Technologies Global Corp.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.